<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108600</url>
  </required_header>
  <id_info>
    <org_study_id>ML29092</org_study_id>
    <nct_id>NCT02108600</nct_id>
  </id_info>
  <brief_title>Tocilizumab for Renal Graft Inflammation</brief_title>
  <official_title>A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flavio Vincenti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized open label clinical trial in which 48 renal transplant recipients with&#xD;
      inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or&#xD;
      receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual&#xD;
      immunosuppression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized controlled study of kidney transplant recipients with SCI on&#xD;
      6-month surveillance kidney biopsies. SCI for the purpose of this study is defined as 10-50%&#xD;
      total parenchymal mononuclear inflammation (Banff ti1-ti2) with &lt;i2,t2 concurrent lesions.&#xD;
&#xD;
      After enrollment, study participants subjects will be randomized to group 1 (standard of care&#xD;
      group) or group 2 (tocilizumab (TCZ) group). Block randomization will be performed by the&#xD;
      UCSF investigational pharmacy using computer-generated random numbers. The pathologist will&#xD;
      be blinded to the randomization.&#xD;
&#xD;
      Group 1 (standard of care group) will continue their usual immunosuppression and not receive&#xD;
      any specific intervention.&#xD;
&#xD;
      Group 2 (TCZ group) will receive tocilizumab 8 mg/kg intravenously at four-week intervals for&#xD;
      a total of 6 doses.In addition, they will continue their usual immunosuppressive regimen.&#xD;
&#xD;
      As noted above, both groups will continue their usual maintenance immunosuppression regimen.&#xD;
      Therefore, recipients who are already receiving prednisone will continue it at 5 mg/day.&#xD;
      Recipients on prednisone-free regimens will remain prednisone-free. Mycophenolate mofetil&#xD;
      will be continued at the same dose as at the time of the biopsy. Tacrolimus dosing will be&#xD;
      adjusted to aim for trough levels of 5-8 mcg/L.&#xD;
&#xD;
      The study period will be 12 months (6 months of therapy plus 6 months of extended follow up-&#xD;
      see Study Schema). Any episodes of infections, renal allograft dysfunctions, rejections or&#xD;
      other clinical events during the study period will be treated per the usual standard of care.&#xD;
&#xD;
      All participants will be seen by the study PI or co-investigator at monthly study visits. A&#xD;
      focused history and physical exam will be performed, including queries for drug toxicities&#xD;
      and signs/ symptom of infections. All participants will obtain laboratory tests at intervals&#xD;
      of 4 weeks, consisting of a complete blood count, serum electrolytes, BUN and serum&#xD;
      creatinine, fasting glucose, liver function tests and 12-hour trough tacrolimus levels. Lipid&#xD;
      panels will be obtained at baseline, then every 12 weeks an at study termination.The&#xD;
      outpatient electronic medical record will be queried twiceweekly by the study coordinator for&#xD;
      any new laboratory results on study participants. Laboratory data on all study participants&#xD;
      will be reviewed weekly by the study PI.&#xD;
&#xD;
      The 12-month surveillance biopsy will be performed at the end of therapy (6 months after&#xD;
      study enrollment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">December 16, 2018</completion_date>
  <primary_completion_date type="Actual">December 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Proportion of participants in each group who had a 1 point decrease in inflammation based on Banff scoring on renal allograft biopsy at 6 months compared to baseline. The Banff ti- score can be 0, 1, 2 or 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Cytokines</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in urinary cytokines from baseline at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Donor Specific Anti-HLA Antibodies</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Proportion of participants who developed de novo DSA from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Rejection</measure>
    <time_frame>In the interval between baseline and 6 Months</time_frame>
    <description>Proportion of patients with acute rejection in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Late Complication From Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab (TCZ) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
    <arm_group_label>Tocilizumab (TCZ) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All kidney transplant recipients with SCI on 6-month surveillance biopsy.&#xD;
&#xD;
          -  Maintenance immunosuppression regimens containing tacrolimus and MMF with or without&#xD;
             prednisone.&#xD;
&#xD;
          -  Ability to provide written informed consent for the study.&#xD;
&#xD;
          -  Men and women of reproductive potential must agree to use an acceptable method of&#xD;
             birth control during treatment and for six months after completion of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
        â€¢ Major surgery (including joint surgery) within 8 weeks prior to screening or planned&#xD;
        major surgery within 6 months following randomization.&#xD;
&#xD;
        Excluded Previous or Concomitant Therapy:&#xD;
&#xD;
          -  Treatment with any investigational agent within 4 weeks (or 5 half-lives of the&#xD;
             investigational drug, whichever is longer) of screening.&#xD;
&#xD;
          -  Previous treatment with any cell-depleting therapies, including investigational agents&#xD;
             or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3,&#xD;
             anti-CD19 and anti-CD20, except Thymoglobulin.&#xD;
&#xD;
          -  Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6&#xD;
             months of baseline.&#xD;
&#xD;
          -  Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.&#xD;
&#xD;
          -  Previous treatment with TCZ (an exception to this criterion may be granted for single&#xD;
             dose exposure upon application to the sponsor on a case-by-case basis).&#xD;
&#xD;
          -  Any previous treatment with alkylating agents such as chlorambucil, or with total&#xD;
             lymphoid irradiation.&#xD;
&#xD;
        Exclusions for General Safety:&#xD;
&#xD;
          -  Presence of acute cellular (Banff Type 1-3) or antibody-mediated rejection on 6-month&#xD;
             surveillance biopsy or on biopsies for-cause in the previous 6 months.&#xD;
&#xD;
          -  History of positive urine or serum screening for BK virus (defined as a quantitative&#xD;
             BK virus PCR in urine &gt; 0.5 million copies/ml or any detectable BK viremia) within the&#xD;
             first 6 months post-transplant.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to human, humanized or murine&#xD;
             monoclonal antibodies.&#xD;
&#xD;
          -  Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary&#xD;
             (including obstructive pulmonary disease), renal, hepatic, endocrine (include&#xD;
             uncontrolled diabetes mellitus) or gastrointestinal disease (including diverticulitis,&#xD;
             ulcerative colitis, or Crohn's disease.)&#xD;
&#xD;
          -  Current liver disease as determined by principal investigator unless related to&#xD;
             primary disease under investigation.&#xD;
&#xD;
          -  Known active current or history of recurrent bacterial, viral, fungal, mycobacterial&#xD;
             or other infections (including but not limited to tuberculosis and atypical&#xD;
             mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal&#xD;
             infections of nail beds).&#xD;
&#xD;
          -  Any major episode of infection requiring hospitalization or treatment with IV&#xD;
             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Active TB requiring treatment within the previous 3 years. Patients should be screened&#xD;
             for latent TB and, if positive, treated following local practice guidelines prior to&#xD;
             initiating TCZ. Patients treated for tuberculosis with no recurrence in 3 years are&#xD;
             permitted. (Appendix 8).&#xD;
&#xD;
          -  Primary or secondary immunodeficiency (history of or currently active) unless related&#xD;
             to primary disease under investigation.&#xD;
&#xD;
          -  Evidence of active malignant disease, malignancies diagnosed within the previous 10&#xD;
             years (including hematological malignancies and solid tumors, except basal and&#xD;
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has&#xD;
             been excised and cured), or breast cancer diagnosed within the previous 20 years&#xD;
             unless related to primary disease under investigation.&#xD;
&#xD;
          -  Pregnant women or nursing (breast feeding) mothers.&#xD;
&#xD;
          -  Patients with reproductive potential not willing to use an effective method of&#xD;
             contraception.&#xD;
&#xD;
          -  History of alcohol, drug or chemical abuse within 1 year prior to screening.&#xD;
&#xD;
          -  Patients with lack of peripheral venous access.&#xD;
&#xD;
        Laboratory Exclusion criteria (at screening):&#xD;
&#xD;
          -  Serum creatinine &gt; 1.6 mg/dL (141 Âµmol/L) in female patients and &gt; 1.9 mg/dL (168&#xD;
             Âµmol/L) in male patients. Patients with serum creatinine values exceeding limits may&#xD;
             be eligible for the study if their estimated glomerular filtration rates (GFR) are &gt;30&#xD;
             ml/min/1.73 m2.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 1.5 times upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Total Bilirubin &gt; 1.5 times ULN&#xD;
&#xD;
          -  Platelet count &lt; 100 x 109/L (100,000/mm3)&#xD;
&#xD;
          -  Hemoglobin &lt; 85 g/L (8.5 g/dL; 5.3 mmol/L)&#xD;
&#xD;
          -  White Blood Cells &lt; 3.0 x 109/L (3000/mm3)&#xD;
&#xD;
          -  Absolute Neutrophil Count &lt; 2.0 x 109/L (2000/mm3)&#xD;
&#xD;
          -  Absolute Lymphocyte Count &lt; 0.5 x 109/L (500/mm3)&#xD;
&#xD;
          -  Positive Hepatitis BsAg, or Hepatitis C antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Vincenti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378-83.</citation>
    <PMID>14961990</PMID>
  </reference>
  <reference>
    <citation>Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR. Effect of histological damage on long-term kidney transplant outcome. Transplantation. 2001 Feb 27;71(4):515-23.</citation>
    <PMID>11258430</PMID>
  </reference>
  <reference>
    <citation>Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33.</citation>
    <PMID>14668458</PMID>
  </reference>
  <reference>
    <citation>Cosio FG, Grande JP, Larson TS, Gloor JM, Velosa JA, Textor SC, Griffin MD, Stegall MD. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant. 2005 May;5(5):1130-6.</citation>
    <PMID>15816896</PMID>
  </reference>
  <results_reference>
    <citation>Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial. Am J Transplant. 2021 Jul;21(7):2543-2554. doi: 10.1111/ajt.16459. Epub 2021 Jan 21.</citation>
    <PMID>33331082</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Flavio Vincenti</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02108600/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
        </group>
        <group group_id="P2">
          <title>Tocilizumab (TCZ) Group</title>
          <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15">1 patient lost to follow up after the primary endpoint biopsy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>n=17 signed consent but 3 withdrew before primary endpoint (2 of them before visit 1) Therefore n=14 were analyzed for baseline characteristics</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
        </group>
        <group group_id="B2">
          <title>Tocilizumab (TCZ) Group</title>
          <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive reg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" lower_limit="40" upper_limit="56"/>
                    <measurement group_id="B2" value="53.5" lower_limit="41.5" upper_limit="59"/>
                    <measurement group_id="B3" value="52" lower_limit="40" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months</title>
        <description>Proportion of participants in each group who had a 1 point decrease in inflammation based on Banff scoring on renal allograft biopsy at 6 months compared to baseline. The Banff ti- score can be 0, 1, 2 or 3.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab (TCZ) Group</title>
            <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months</title>
          <description>Proportion of participants in each group who had a 1 point decrease in inflammation based on Banff scoring on renal allograft biopsy at 6 months compared to baseline. The Banff ti- score can be 0, 1, 2 or 3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Cytokines</title>
        <description>Change in urinary cytokines from baseline at 6 months.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The urine samples were not adequate for analysis and therefore this outcome was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab (TCZ) Group</title>
            <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Cytokines</title>
          <description>Change in urinary cytokines from baseline at 6 months.</description>
          <population>The urine samples were not adequate for analysis and therefore this outcome was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Donor Specific Anti-HLA Antibodies</title>
        <description>Proportion of participants who developed de novo DSA from baseline to 6 months</description>
        <time_frame>From baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab (TCZ) Group</title>
            <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Donor Specific Anti-HLA Antibodies</title>
          <description>Proportion of participants who developed de novo DSA from baseline to 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute Rejection</title>
        <description>Proportion of patients with acute rejection in each group</description>
        <time_frame>In the interval between baseline and 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab (TCZ) Group</title>
            <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Rejection</title>
          <description>Proportion of patients with acute rejection in each group</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>used Common Terminology Criteria for Adverse Events (CTCAE) grades</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Will continue usual immunosuppression and not receive any specific intervention.</description>
        </group>
        <group group_id="E2">
          <title>Tocilizumab (TCZ) Group</title>
          <description>Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.&#xD;
Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <description>pneumonia + sepsis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>subcapsular hematoma</sub_title>
                <description>post primary endpoint biopsy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study could not meet its recruitment target of 48 subjects, and consequently, is underpowered statistically. Additionally, the urine samples were inadequate, leading to inability to perform urine cytokine measurements.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sindhu Chandran</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>4153538374</phone>
      <email>sindhu.chandran@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

